| Literature DB >> 30446572 |
Bernie Carter1, Enitan D Carrol2, David Porter3, Matthew Peak4, David Taylor-Robinson5, Debra Fisher-Smith2, Lucy Blake1.
Abstract
BACKGROUND: There has been little detailed systematic consideration of the delivery, setting and outcomes of paediatric Outpatient Parenteral Antimicrobial Therapy (OPAT), although individual studies report that it is a safe and effective treatment.Entities:
Keywords: infectious diseases
Mesh:
Substances:
Year: 2018 PMID: 30446572 PMCID: PMC6252693 DOI: 10.1136/bmjopen-2018-021603
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Inclusion and exclusion criteria
| Inclusion criteria | Exclusion criteria |
|
Primary research studies. Articles in peer-reviewed journals. Published in English. Data are presented from children and young people aged 21 years or under (and are reported separately from adults' data). Children and young people who received Outpatient Parenteral Antimicrobial Therapy treatment did so in their home or a day treatment centre and data from inpatients and outpatients were reported separately. Children and young people received at least 80% of treatment intravenously. Data from intramuscular and intravenous treatment reported separately. |
Studies conducted in developing/low-income settings. The full text of the article was unavailable. Case studies, reviews, guidelines, poster, abstracts, commentaries and editorials. |
Search terms (by population, concept, context)
| OPAT | Population (<21 years) |
Paediatric OR pediatric OR infant OR child* OR adolesce* Infection OR infectious disease |
| Concept (Intervention) |
Antibiotic OR antimicrobial AND (agent OR therapy OR prescri* OR manage*) Parenteral OR intravenous infusion OR home infusion | |
| Context (Setting) |
Outpatient OR home OR ambulatory OR community |
MMAT synthesis table
| Type of study | Methodological quality criteria | Randomised Controlled Trial | Quantitative descriptive | |||||||||||||||||
| Gupta | Orme | Banerjee | Campo | Peláez Cantero | Doré-Bergeron | Gauthier | Glackin | Goldman | Gomez | Hodgson | Le | Madigan and Banerjee | Maraqa | Reid and Bonadio | Shemesh | Van der Laag and Van de Weg | Van Winkle | Wiernikowski | ||
| Screening questions | Are there clear research question(s)? | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | Y |
| Do the data address the research question? | Y | Y | Y | Y | Y | Y | UC | UC | Y | UC | UC | Y | Y | Y | Y | UC | UC | UC | ||
| RCT | Is there a clear description of randomisation? | Y | Y | |||||||||||||||||
| Is there a clear description of concealment? | N | N | ||||||||||||||||||
| Are there complete outcome data? | UC | Y | ||||||||||||||||||
| Is there low withdrawal? | Y | Y | ||||||||||||||||||
| Quant. Descript. | Is the sampling strategy relevant? | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | ||
| Is the sample representative? | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | UC | |||
| Are measurements appropriate? | UC | Y | Y | Y | Y | UC | Y | UC | Y | Y | Y | Y | UC | Y | UC | UC | UC | |||
| Is there an acceptable response rate? | N | Y | Y | Y | Y | UC | UC | UC | Y | Y | Y | Y | Y | Y | UC | Y | UC | |||
MMAT, Mixed Methods Appraisal Tool; N, no; Y, yes; UC, unclear.
Figure 1Flow diagram for scoping review process (from Joanna Briggs Institute manual).